Kura Oncology (NASDAQ:KURA) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report released on Monday, Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock.

A number of other analysts have also commented on KURA. Wedbush reiterated an outperform rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Wednesday, February 28th. JMP Securities raised their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a report on Wednesday, January 31st. Finally, StockNews.com downgraded shares of Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $28.28.

Kura Oncology Stock Up 3.8 %

NASDAQ:KURA opened at $18.19 on Monday. The firm has a market cap of $1.39 billion, a P/E ratio of -8.75 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The firm has a 50-day simple moving average of $20.73 and a two-hundred day simple moving average of $15.35.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same quarter in the prior year, the business earned ($0.49) earnings per share. Analysts predict that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, CEO Troy Edward Wilson sold 91,052 shares of Kura Oncology stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the transaction, the chief executive officer now owns 559 shares of the company’s stock, valued at $11,308.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Troy Edward Wilson sold 91,052 shares of Kura Oncology stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the sale, the chief executive officer now owns 559 shares in the company, valued at $11,308.57. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Kathleen Ford sold 1,496 shares of Kura Oncology stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the sale, the chief operating officer now owns 21,602 shares in the company, valued at approximately $384,515.60. The disclosure for this sale can be found here. Insiders have sold 96,919 shares of company stock valued at $1,946,415 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC raised its position in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after buying an additional 1,449 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Kura Oncology by 352.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares during the last quarter. Saxon Interests Inc. bought a new stake in Kura Oncology in the first quarter worth $201,000. Pale Fire Capital SE bought a new stake in Kura Oncology in the third quarter worth $92,000. Finally, E Fund Management Co. Ltd. increased its position in Kura Oncology by 12.2% in the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after purchasing an additional 1,301 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.